Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Rho GTPase-activating protein 12 (ARHGAP12)
- Target
- ARHGAP12
- Molecular classification
- Enzyme, Rho GTPase activating protein, Cytoskeletal regulatory protein
01
Overview
Rho GTPase-activating protein 12 (ARHGAP12) is a member of the RhoGAP family of enzymes that inactivate Rho-type GTPases (particularly Rac1), playing crucial roles in the regulation of the actin cytoskeleton, cell adhesion, migration, and invasion. ARHGAP12 is expressed in various tissues and cell types, including epithelial cells and neurons. Functionally, it controls focal adhesion formation, thus influencing cell-matrix interactions, and modulates synaptic development by regulating dendritic spine size and AMPA receptor endocytosis. In cancer biology, ARHGAP12 overexpression is associated with tumor aggressiveness and resistance to tyrosine kinase inhibitors in hepatocellular carcinoma, making it a potential therapeutic target and biomarker of disease progression and treatment response[1][2][4][5][9][10].
- Other names
- Rho GTPase activating protein 12ARHGAP12FLJ20737FLJ10971FLJ21785Rho-type GTPase-activating protein 12
02
Mechanism of action
Regulation of focal adhesion pathway, Modulation of Rac1 activity, Regulation of actin cytoskeleton dynamics, Mediation of cell adhesion
03
Biological functions
Actin filament organizationCell adhesionCell signalingCell invasionCell migrationSynaptic structure regulationCell differentiation
04
Disease associations
CancerTyrosine kinase inhibitor resistanceEarly-onset colorectal cancerBladder pain syndromeNeurological/developmental disorders
05
Safety considerations
Potential for promoting tumor invasion/adhesion in cancerTherapeutic challenges include TKI resistanceInvolvement in diverse tissue homeostasis may raise concerns for off-target effects
06
Interacting drugs
Sorafenib
5 more in the full profile.
07
Biomarkers
High ARHGAP12 expression as a prognostic biomarker for hepatocellular carcinoma (poor prognosis)Marker for TKI resistance in HCC
Beyond the preview
Go deeper on Rho GTPase-activating protein 12 (ARHGAP12).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rho GTPase-activating protein 12 (ARHGAP12).